← Back to screener

ArriVent BioPharma, Inc. AVBP

Rank #1725 · Nasdaq · $0.7B market cap
Audited by PricewaterhouseCoopers LLP, no going-concern flag in the latest filing.
Score
43.5
P/E
-8.6
P/B
-4.52
ROE
52.5%
Op. Margin
–%
Debt Ratio
-11%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Poor

P/E -8.6x, P/B -4.52x. Ranks in the top 93% of the universe.

Profitability ★★★★★
Excellent

ROE 52.5%. Ranks in the top 7% of the universe.

Safety ★★★★★
Excellent

Debt ratio -11%. Ranks in the top 7% of the universe. Under 100% is generally considered a safe level.

Growth –
No data

Not enough historical filings to compute year-over-year growth yet.

Profitability is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2024–$-0.1B$-0.1B$-0.1B–-14
2025–$-0.1B$-0.1B$-0.2B–-11

← See the full screener